Does Thiazolidinedione therapy exacerbate fluid retention in congestive heart failure

摘要: The ever-growing global burden of congestive heart failure (CHF) and type 2 diabetes mellitus (T2DM) as well their co-existence necessitate that anti-diabetic pharmacotherapy will modulate the cardiovascular risk inherent to T2DM while complying with accompanying restrictions imposed by CHF. thiazolidinedione (TZD) family peroxisome proliferator-activated receptor γ (PPARγ) agonists initially provided a promising therapeutic option in owing efficacy combined pleiotropic beneficial effects. However, utility TZDs has declined past decade, largely due concomitant adverse effects fluid retention edema formation attributed salt-retaining PPARγ activation on nephron. Presumably, latter are potentially deleterious context pre-existing despite considerable body evidence mechanisms responsible for TZD-induced suggesting this class drugs is rightfully prohibited from use CHF patients, there paucity experimental clinical studies investigate salt water homeostasis setting. In an attempt elucidate whether actually exacerbate CHF, our review summarizes pathophysiology Moreover, we thoroughly available data proposed animals patients. Finally, present recent challenging common notion worsen renal